Tumours treated with nintedanib and gemcitabine combined showed a reduction of both the α-SMA-positive staining area and the proportion of Ki-67-positive ICC cells (Fig. 5b). This evidence concerns the gene MKI67 and intrahepatic cholangiocarcinoma.